Dmitry A Butov

Summary

Country: Russia

Publications

  1. doi Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo
    S I Zaitzeva
    Department of Phtysiatry and Pulmonology, Kharkov National Medical University, Kharkov, Ukraine
    Clin Microbiol Infect 15:1154-62. 2009
  2. pmc Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB
    Dmitry A Butov
    Department of Phtysiatry and Pulmonology, Kharkov National Medical University Kharkov, Ukraine
    J Immune Based Ther Vaccines 9:3. 2011

Collaborators

  • S I Zaitzeva
  • Y N Pashkov
  • S L Matveeva
  • V S Pylypchuk
  • V M Frolov
  • G A Kutsyna
  • T G Gerasimova

Detail Information

Publications2

  1. doi Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo
    S I Zaitzeva
    Department of Phtysiatry and Pulmonology, Kharkov National Medical University, Kharkov, Ukraine
    Clin Microbiol Infect 15:1154-62. 2009
    ..008, 0.25 and 0.72, and 0.013, 0.48 and 0.0015. Dzherelo is thus useful as an immunotherapeutic adjunct in the management of TB...
  2. pmc Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB
    Dmitry A Butov
    Department of Phtysiatry and Pulmonology, Kharkov National Medical University Kharkov, Ukraine
    J Immune Based Ther Vaccines 9:3. 2011
    ..9/1.5 vs. 1.8/1; P = 0.34). No adverse effects or TB reactivation were seen at any time during follow-up. V5 is safe as an immune adjunct to chemotherapeutic management of TB and can shorten substantially the duration of treatment...